e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
New bronchodilators for COPD management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
J. H. Ficker, J. A. Wedzicha, M. Decramer, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Nuernberg, Germany; London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America)
Source:
Annual Congress 2013 –New bronchodilators for COPD management
Session:
New bronchodilators for COPD management
Session type:
Oral Presentation
Number:
182
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. H. Ficker, J. A. Wedzicha, M. Decramer, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Nuernberg, Germany; London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America). QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study. Eur Respir J 2013; 42: Suppl. 57, 182
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
FORWARD: A study of extrafine beclomethasone/formoterol compared with formoterol alone in patients with severe COPD and a history of exacerbations
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: Pooled data
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Baseline symptom scores and future risk of severe exacerbation: The SPARK study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
COPD: Influence of patients’ nutritive status on the exacerbations rate
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
The relation of comorbidities with the exacerbation severity in patients with COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Characterization of readmissions in patients hospitalized with COPD exacerbation
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
A global survey conducted to determine frequency of exacerbations in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Compare clinical effectiveness of various types of bronchodilators in COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Real life assessment of inhaler use and acute exacerbations in 2935 COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept